Modality
Peptide
MOA
JAK1i
Target
TYK2
Pathway
PI3K/AKT
FL
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
Oct 2019
→ Jul 2031
Phase 1Current
NCT03953622
2,900 pts·FL
2019-10→2031-07·Active
2,900 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-285.3y awayPh2 Data· FL
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Active
Catalysts
Ph2 Data
2031-07-28 · 5.3y away
FL
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03953622 | Phase 1/2 | FL | Active | 2900 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| ROI-1081 | Roivant Sciences | Phase 1/2 | PI3Kα | |
| COR-9566 | Corcept | Approved | TYK2 | |
| SND-9531 | Syndax | Phase 3 | TYK2 |